NCT01037166View on ClinicalTrials.gov

Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Chronic Hepatitis B
Interventions
DRUG

Entecavir

Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks

Trial Locations (16)

480-1195

Local Institution, Aichi-Gun

466-8550

Local Institution, Nagoya

467-8602

Local Institution, Nagoya

Unknown

Local Institution, Chiba

Local Institution, Kurume

Local Institution, Kyoto

Local Institution, Sendai

503-8502

Local Institution, Ogaki-Shi

070-0054

Local Institution, Asahikawa-Shi

060-0033

Local Institution, Sapporo

673-0848

Local Institution, Akashi-Shi

020-8505

Local Institution, Morioka

700-0082

Local Institution, Okayama

105-0001

Local Institution, Minato-Ku

180-0023

Local Institution, Musashino-Shi

162-8666

Local Institution, Shinjuku-Ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01037166 - Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy | Biotech Hunter | Biotech Hunter